Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.OQ)

PPHM.OQ on NASDAQ Stock Exchange Capital Market

3.23USD
18 Aug 2017
Change (% chg)

$0.15 (+4.87%)
Prev Close
$3.08
Open
$3.04
Day's High
$3.26
Day's Low
$2.99
Volume
49,172
Avg. Vol
52,708
52-wk High
$5.77
52-wk Low
$1.98

Select another date:

Fri, Aug 11 2017

BRIEF-Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

* Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

BRIEF-Peregrine ‍says "to evaluate strategic options for advancing research and development business​"

* Peregrine Pharmaceuticals Inc - ‍continues to evaluate strategic options for advancing research and development business​

BRIEF-Ronin Trading, SW Investment Management issue letter to Peregrine Pharma employees​

* ‍Ronin Trading and SW Investment Management say issued a letter to Peregrine Pharmaceuticals' employees​

BRIEF-Peregrine Pharmaceuticals Q4 revenue $17.9 million

* Peregrine Pharmaceuticals reports financial results for quarter and fiscal year ended April 30, 2017 and recent developments

BRIEF-Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals

* Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals

BRIEF-Peregrine Pharmaceuticals presents preliminary correlative analysis of PD-l1 expression from sunrise trial

* Peregrine Pharmaceuticals presents preliminary correlative analysis of pd-l1 expression from sunrise trial at asco 2017

BRIEF-Ronin Capital LLC reports 5.8 pct stake in Peregrine Pharmaceuticals

* Ronin Capital LLC reports 5.8 percent stake in Peregrine Pharmaceuticals Inc as of April 6 - sec filing Source text : http://bit.ly/2prmM8N Further company coverage:

BRIEF-Peregrine Pharma presents data for Bavituximab's anti-tumor enhancing activity

* Peregrine Pharmaceuticals highlights clinical data presentation at aacr 2017 annual meeting supporting potential of Bavituximab to enhance anti-tumor activity of immunotherapy

BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04

* Sees FY 2017 revenue from avid bioservices business of $60 million-$65 million

BRIEF-Ronin Capital reports 6.8 pct stake in Peregrine pharma as of feb 21 - SEC filing

* As of feb 21 Ronin Capital Llc Reports 6.8 Pct Stake In Peregrine Pharmaceuticals Inc- SEC filing Source text for Eikon: [ID:http://bit.ly/2lyZfNi] Further company coverage:

Select another date: